These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 31239195)

  • 1. Impact of flavin-containing monooxygenase 3 and CYP2C19 genotypes on plasma disposition and adverse effects of voriconazole administered orally in immunocompromised patients.
    Yamada T; Mino Y; Naito T; Kawakami J
    J Infect Chemother; 2019 Dec; 25(12):1019-1025. PubMed ID: 31239195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive Value of FMO3 Variants on Plasma Disposition and Adverse Reactions of Oral Voriconazole in Febrile Neutropenia.
    Wang X; Zhao J; Wen T; Liao X; Luo B
    Pharmacology; 2021; 106(3-4):202-210. PubMed ID: 32998136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of CYP2C19, CYP2C9, CYP3A4, and FMO3 Genetic Polymorphisms and Sex on the Pharmacokinetics of Voriconazole after Single and Multiple Doses in Healthy Chinese Subjects.
    Liu S; Yao X; Tao J; Zhao S; Sun S; Wang S; Tian X
    J Clin Pharmacol; 2024 Aug; 64(8):1030-1043. PubMed ID: 38654529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
    Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
    Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections.
    Chuwongwattana S; Jantararoungtong T; Prommas S; Medhasi S; Puangpetch A; Sukasem C
    Pharmacol Res Perspect; 2020 Dec; 8(6):e00665. PubMed ID: 33124772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers.
    Lee S; Kim BH; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    J Clin Pharmacol; 2012 Feb; 52(2):195-203. PubMed ID: 21383338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients.
    Lin XB; Li ZW; Yan M; Zhang BK; Liang W; Wang F; Xu P; Xiang DX; Xie XB; Yu SJ; Lan GB; Peng FH
    Br J Clin Pharmacol; 2018 Jul; 84(7):1587-1597. PubMed ID: 29607533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Saturated Metabolism of Voriconazole N-Oxidation Resulting in Nonlinearity of Pharmacokinetics of Voriconazole at Clinical Doses.
    Yamada T; Mino Y; Yagi T; Naito T; Kawakami J
    Biol Pharm Bull; 2015; 38(10):1496-503. PubMed ID: 26424015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasive Aspergillus infection requiring lobectomy in a CYP2C19 rapid metabolizer with subtherapeutic voriconazole concentrations.
    Hicks JK; Gonzalez BE; Zembillas AS; Kusick K; Murthy S; Raja S; Gordon SM; Hanna R
    Pharmacogenomics; 2016 May; 17(7):663-7. PubMed ID: 27143031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects.
    Zhu L; Brüggemann RJ; Uy J; Colbers A; Hruska MW; Chung E; Sims K; Vakkalagadda B; Xu X; van Schaik RH; Burger DM; Bertz RJ
    J Clin Pharmacol; 2017 Feb; 57(2):235-246. PubMed ID: 27432796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole.
    Klomp SD; Veringa A; Alffenaar JC; de Boer MGJ; Span LFR; Guchelaar HJ; Swen JJ
    Clin Transl Sci; 2024 Jul; 17(7):e13887. PubMed ID: 39010708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
    Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
    Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
    Hamadeh IS; Klinker KP; Borgert SJ; Richards AI; Li W; Mangal N; Hiemenz JW; Schmidt S; Langaee TY; Peloquin CA; Johnson JA; Cavallari LH
    Pharmacogenet Genomics; 2017 May; 27(5):190-196. PubMed ID: 28306618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3.
    Yanni SB; Annaert PP; Augustijns P; Ibrahim JG; Benjamin DK; Thakker DR
    Drug Metab Dispos; 2010 Jan; 38(1):25-31. PubMed ID: 19841059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.
    Scholz I; Oberwittler H; Riedel KD; Burhenne J; Weiss J; Haefeli WE; Mikus G
    Br J Clin Pharmacol; 2009 Dec; 68(6):906-15. PubMed ID: 20002085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship Between the CYP2C19 Phenotype Using the Voriconazole-to-Voriconazole N-Oxide Plasma Concentration Ratio and Demographic and Clinical Characteristics of Japanese Patients With Different CYP2C19 Genotypes.
    Niioka T; Fujishima N; Abumiya M; Yamashita T; Ubukawa K; Nara M; Fujishima M; Takahashi N; Miura M
    Ther Drug Monit; 2017 Oct; 39(5):514-521. PubMed ID: 28834922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of age and CYP2C19 genotypes on voriconazole steady-state trough concentration in Chinese patients.
    Du YX; Zhu YX; Li L; Yang J; Chen XP
    Pharmacogenet Genomics; 2024 Aug; 34(6):191-198. PubMed ID: 38747453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of Adverse Events and Determinants of the Voriconazole Trough Concentration in Kidney Transplantation Recipients.
    Zhao YC; Lin XB; Zhang BK; Xiao YW; Xu P; Wang F; Xiang DX; Xie XB; Peng FH; Yan M
    Clin Transl Sci; 2021 Mar; 14(2):702-711. PubMed ID: 33202102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.
    Lee J; Ng P; Hamandi B; Husain S; Lefebvre MJ; Battistella M
    Ann Pharmacother; 2021 Apr; 55(4):509-529. PubMed ID: 32772568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles.
    Chung H; Lee H; Han HK; An H; Lim KS; Lee YJ; Cho JY; Yoon SH; Jang IJ; Yu KS
    Drug Des Devel Ther; 2015; 9():2609-16. PubMed ID: 25999694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.